Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

FibroGen Inc

FGEN
Current price
0.29 USD +0.015 USD (+5.45%)
Last closed 0.27 USD
ISIN US31572Q8087
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 28 892 538 USD
Yield for 12 month -74.89 %
1Y
3Y
5Y
10Y
15Y
FGEN
21.11.2021 - 28.11.2021

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Address: 350 Bay Street, San Francisco, CA, United States, 94133

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.00 USD

P/E ratio

Dividend Yield

Current Year

+29 621 000 USD

Last Year

+147 752 000 USD

Current Quarter

-123 256 000 USD

Last Quarter

+46 333 000 USD

Current Year

+14 060 000 USD

Last Year

+128 904 000 USD

Current Quarter

-102 590 000 USD

Last Quarter

+41 038 000 USD

Key Figures FGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -128 270 000 USD
Operating Margin TTM -198.79 %
Price to Earnings
Return On Assets TTM -25.66 %
PEG Ratio
Return On Equity TTM -1 015.79 %
Wall Street Target Price 10.00 USD
Revenue TTM 29 621 000 USD
Book Value -2.24 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 15.40 %
Dividend Yield
Gross Profit TTM -81 632 000 USD
Earnings per share -1.53 USD
Diluted Eps TTM -1.53 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY 53.60 %
Profit Margin -160.63 %

Dividend Analytics FGEN

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History FGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio
Last Split Date

Stock Valuation FGEN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 61.35
Enterprise Value Revenue 1.74
Price Sales TTM 0.98
Enterprise Value EBITDA -0.17
Price Book MRQ 53.83

Financials FGEN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators FGEN

For 52 weeks

0.18 USD 1.74 USD
50 Day MA 0.40 USD
Shares Short Prior Month 4 978 990
200 Day MA 0.47 USD
Short Ratio 2.92
Shares Short 4 668 238
Short Percent 5.44 %